anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cardiovascular complications pose a significant burden in type 2 diabetes mellitus (T2DM), driven by the intricate interplay of chronic hyperglycemia, insulin resistance, and lipid metabolism disturbances. Myocardial ischemia/reperfusion (MI/R) injury during cardiopulmonary bypass (CPB) exacerbates cardiac vulnerability. This study aims to probe the role of Caspase-1-dependent pyroptosis in global ischemia/reperfusion injury among T2DM rats undergoing CPB, elucidating the mechanisms underlying heightened myocardial injury in T2DM. This study established a rat model of T2DM and compared Mean arterial pressure (MAP), heart rate (HR), and hematocrit (Hct) between T2DM and normal rats. Myocardial cell morphology, infarction area, mitochondrial ROS and caspase-1 levels, NLRP3, pro-caspase-1, caspase-1 p10, GSDMD expressions, plasma CK-MB, cTnI, IL-1β, and IL-18 levels were assessed after reperfusion in both T2DM and normal rats. The role of Caspase-1-dependent pyroptosis in myocardial ischemia/reperfusion injury during CPB in T2DM rats was examined using the caspase-1 inhibitor VX-765 and the ROS scavenger NAC. T2DM rats demonstrated impaired glucose tolerance but stable hemodynamics during CPB, while showing heightened vulnerability to MI/R injury. This was marked by substantial lipid deposition, disrupted myocardial fibers, and intensified cellular apoptosis. The activation of caspase-1-mediated pyroptosis and increased reactive oxygen species (ROS) production further contributed to tissue damage and the ensuing inflammatory response. Notably, myocardial injury was mitigated by inhibiting caspase-1 through VX-765, which also attenuated the inflammatory cascade. Likewise, NAC treatment reduced oxidative stress and partially suppressed ROS-mediated caspase-1 activation, resulting in diminished myocardial injury. This study proved that Caspase-1-dependent pyroptosis significantly contributes to the inflammation and injury stemming from global MI/R in T2DM rats under CPB, which correlate with the surplus ROS generated by oxidative stress during reperfusion.
Voclosporin is a next generation CNI intended for use in the prevention of organ graft rejection and for the treatment of autoimmune diseases. The aim of the current study is to investigate whether voclosporin added to the standard of care treatment in active LN is able to reduce disease activity, as measured by a reduction in proteinuria. Two doses of voclosporin will be studied and compared in a placebo controlled trial on a background of MMF and corticosteroids. Patients with active, flaring LN will be eligible to enter the study. They are required to have a diagnosis of LN according to established diagnostic criteria (American College of Rheumatology) and clinical and biopsy features suggestive of active nephritis. Efficacy will be assessed by the ability of the drug combination to reduce the level of proteinuria while demonstrating an acceptable safety profile.
Participants will be counseled to follow a standard weight-reducing diet including consumption of 1) ample vegetables, fruits, and legumes; 2) whole rather than refined grains; and 3) high-quality proteins at most meals and snacks. Moreover, we will recommend limiting intake of added fats and sugars and avoiding juices and sugar-sweetened beverages (per standard practice). Participants will also be counseled to increase their water intake to 8 cups per day, consistent with the popular "8 × 8" recommendation (eight 8-oz glasses of water).
The participants randomized to the control arm had the same testing as those in the treatment arm and were offered teriparatide, if determined to be effective in healing bone erosions, after the first 12 months. All participants received daily 1000 mg of calcium citrate, 800 IU of vitamin D and a TNF antagonist.
The T.E.S.S.® (Total Evolutive Shoulder System) was developed to provide, with one instrumentation, a complete solution for all indications for shoulder arthroplasty: centered and eccentric rheumatoid osteoarthritis, necrosis, proximal fracture and mal-union of the humeral head. The T.E.S.S.® Modular system can be used in anatomic or reverse configurations with or without the use of a stem, providing a solution for hemi-arthroplasty, total shoulder arthroplasty and revision. The same instrumentation allows implantation of all versions of the T.E.S.S.®.

A maximum of 5 study centers will be involved in Europe. A total number of 146 implants, 73 T.E.S.S.® anatomic and 73 T.E.S.S.® reverse, will be included into the study. Each clinical site will be allowed to enroll a maximum 88 patients (60% of the total study cohort). Ethics Committee (EC) approval has to be obtained prior to conducting this study. All potential subjects will be required to participate in an informed consent process and sign the EC approved written informed consent prior to study enrollment.
Participants receive a single dose of Placebo in ADP Session 1. After a 1 week washout period, they undergo ADP Session 2 in which they receive a single dose of Lacosamide 200 mg. After another 1 week washout period, they undergo ADP Session 3 in which they receive a single dose of Lacosamide 100 mg.
Participants will receive a single oral dose of decitabine and tetrahydrouridine (THU) immediate release tablets (Formulation A) on Day 1 of treatment period 1 followed by a single oral dose of decitabine and THU delayed release capsules (Formulation B) on Day 1 of treatment period 2. A washout period of 7- 21 days will be maintained between the two treatment periods.
PURPOSE:To make a water-insoluble or hardly soluble organic substance soluble in water, by using a specific beta-cyclodextrin oligomer as a solubilizing agent and clathrating the organic substance in the agent. CONSTITUTION:A water-insoluble or hardly soluble organic substance (e.g. indomethacin, ibuprofen, etc., which are nonsteroidal anti-inflammatory agent useful as a poultice, various fat-soluble vitamins, water-insoluble local anesthetics, etc.) is clathrated in a beta-cyclodextrin oligomer (preferably having an average molecular weight of 2,000-10,000) produced by crosslinking beta- cyclodextrin to modify its pyranose ring structure. The amount of the organic substance to be clathrated is 0.1-2mol, especially about 1mol per 1mol of beta- cyclodextrin. The solubilized substance can be easily dissolved in water to form an aqueous solution.
Prolonged warm ischemic is the main cause discarding donated organs after cardiac death. Here, we identified that prolonged warm ischemic time induced disseminated intravascular coagulation and severe capillary vasospasm after cardiac death of rat kidneys. Additionally, we found a significant accumulation of fibrinogen in a hypoxic cell culture of human umbilical vein epithelial cells and in isolated kidneys exposed to prolonged warm ischemic following flushing out of blood. However, pre-flushing the kidney with snake venom plasmin in a 90-minute warm ischemic model maximized removal of micro thrombi and facilitated the delivery of oxygen and therapeutic agents. Application of carbon monoxide-releasing CORM-401 during ex vivo hypothermic oxygenated perfusion achieved multipath protective effects in prolonged warm ischemic kidneys. This led to significant improvements in perfusion parameters, restoration of the microcirculation, amelioration of mitochondrial injury, oxidative stress, and apoptosis. This benefit resulted in significantly prolonged warm ischemic kidney recipient survival rates of 70%, compared with none in those receiving ex vivo hypothermic oxygenated perfusion alone. Significantly, ex vivo hypothermic oxygenated perfusion combined with cytoprotective carbon monoxide releasing CORM-401 treatment meaningfully protected the donated kidney after cardiac death from ischemia-reperfusion injury by reducing inflammation, oxidative stress, apoptosis, and pathological damage. Thus, our study suggests a new combination treatment strategy to potentially expand the donor pool by increasing use of organs after cardiac death and salvaging prolonged warm ischemic kidneys.
A human ubiquitin conjugating enzyme, designated hUBC-9, its full amino acid sequence, and nucleic acid polymers which encode hUBC-9 are disclosed. In addition to having functional ubiquitin conjugating activity, this enzyme has transcriptional repressor activity which is independent of the conjugating activity. The conjugating activity of hUBC-9 enhances transcription through degradation of transcription suppressor proteins such as WT1, and possibly, of hUBC-9 itself. The repressor activity of hUBC-9 suppress gene transcription, probably by disrupting the transcriptional initiation complex through specific interactions with the DNA binding region of the TATA binding protein (TBP). In use, hUBC-9, yUBC-9 and other ubiquitin conjugating enzymes having repressor activity can be fused to proteins having a DNA binding domain, such as Gal4, or used in conjunction with reppressors such as Wilm's tumor suppressor gene product, WT1. Such enzymes and the nucleic acid polymers encoding them can be used for regulating transcription of a target gene in both pharmaceutical and non-pharmaceutical applications.
The present invention concerns a method of testing whether a living organism has been exposed to stress, such as pesticide exposure, e.g., whether weed crops have been exposed to herbicide. Based on non-separated compounds obtained from an organism, e.g., an extract from a plant, a color development is generated. The color or shade developed is dependent on the compounds of the organism. By comparing the color or shade of the extract obtained from an organism with a standard color scale developed with respect to the same organism, it is possible to determine the final effect of the stress upon the growth of the plant. The invention also concerns a method of providing a standard color scale for material from a living organism that has been exposed to stress, e.g., a pesticide. As assay kit for the determination of the final effect of the stress upon the growth of the plant is also described. The present invention may be used by farmers or advisors to predict the final effect of herbicide treatment of plants before visual signs appear on the plants.
The study involves 22 patients with WSLs at Riyadh Elm University's dental clinics, who will undergo dental examinations and receive ICDAS codes. Group IV uses ICON® resin infiltration, applying a 15% hydrochloric acid solution, rinsing with water, drying, and applying ICON-Dry. Excess resin is removed, and a light curing process is performed. The roughened enamel surface is polished using composite resin polish discs and cups.
Background: Blood pressure (BP) is routinely invasively monitored by an arterial catheter in the intensive care unit (ICU). However, the available data comparing the accuracy of noninvasive methods to arterial catheters for measuring BP in the ICU are limited by small numbers and diverse methodologies. Purpose: To determine agreement between invasive arterial blood pressure monitoring (IABP) and noninvasive blood pressure (NIBP) in critically ill patients. Methods: This was a single center, observational study of critical ill adults in a tertiary care facility evaluating agreement (≤10% difference) between simultaneously measured IABP and NIBP. We measured clinical features at time of BP measurement inclusive of patient demographics, laboratory data, severity of illness, specific interventions (mechanical ventilation and dialysis), and vasopressor dose to identify particular clinical scenarios in which measurement agreement is more or less likely. Results: Of the 1852 critically ill adults with simultaneous IABP and NIBP readings, there was a median difference of 6 mm Hg in mean arterial pressure (MAP), interquartile range (1-12), P < .01. A logistic regression analysis identified 5 independent predictors of measurement discrepancy: increasing doses of norepinephrine (adjusted odds ratio [aOR] 1.10 [95% confidence interval, CI 1.08-1.12] P = .03 for every change in 5 µg/min), lower MAP value (aOR 0.98 [0.98-0.99] P < .01 for every change in 1 mm Hg), higher body mass index (aOR 1.04 [1.01-1.09] P = .01 for an increase in 1), increased patient age (aOR 1.31 [1.30-1.37] P < .01 for every 10 years), and radial arterial line location (aOR 1.74 [1.16-2.47] P = .04). Conclusions: There was broad agreement between IABP and NIBP in critically ill patients over a range of BPs and severity of illness. Several variables are associated with measurement discrepancy; however, their predictive capacity is modest. This may guide future study into which patients may specifically benefit from an arterial catheter.
α-Tocopherylphosphocholine and salts thereof have been discovered to possess antiviral, anti-fungal, anti-inflammatory, PAF-antagonist, and ultra-violet radiation-blocking activities. The compounds are effective to treat a variety of ailments, including diseases of the airways and pulmonary passages. The compound and salts have also been discovered to be capable of forming liposomes. The present invention thus provides methods of treating viral and fungal infections, respiratory disorders, inflammatory disorders and pathophysiological conditions due to PAF activity in a mammal by administering to the mammal α-tocopherylphosphocholine or a pharmaceutically acceptable salt thereof. The invention also provides pharmaceutical compositions comprising α-tocopherylphosphocholine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. Further, the invention provides liposomes which comprise α-tocopherylphosphocholine or a salt thereof as a structural component of the liposome bilayer.
INTRODUCTION: Anti-vascular endothelial growth factor (anti-VEGF) agents may occasionally need to be considered for sight-threatening macular pathology in pregnant and breastfeeding women. This is controversial due to the dearth of data on systemic side effects for mother and child. We aimed to expand the evidence base to inform management.
METHODS: Retrospective case series of pregnant and breastfeeding women treated with intravitreal anti-VEGF injections at Oxford Eye Hospital between January 2015 and December 2022. In addition, we conducted a systematic review and combined eligible cases in a narrative synthesis.
RESULTS: We treated six pregnant women with anti-VEGF for diabetic macular oedema(DMO) (n = 5) or choroidal neovascularisation (CNV) (n = 1). Four received ranibizumab whilst two (not known to be pregnant) received aflibercept. Patients known to be pregnant underwent counselling by an obstetric physician. Five pregnancies resulted in live births. Combining our cases with those previously published, treatment of 41 pregnant women (42 pregnancies) are reported. Indications for treatment included CNV (n = 28/41,68%), DMO (n = 7/41,17%) and proliferative diabetic retinopathy (n = 6/41,15%). Bevacizumab (n = 22/41,54%) and ranibizumab (n = 17/41,41%) were given more frequently than aflibercept (n = 2/41,5%). Many (n = 16/41,40%) were unaware of their pregnancy when treated. Most pregnancies resulted in live births (n = 34/42,81%). First trimester miscarriages (n = 5/42,12%) and stillbirths (n = 3/42,7%) mostly occurred in women with significant risk factors.
CONCLUSION: Intravitreal anti-VEGF injections may not necessarily compromise obstetric outcomes, although clear associations cannot be drawn due to small numbers and confounders from high rates of first trimester miscarriages in general and inherently high-risk pregnancies. It may be worth considering routinely investigating pregnancy and breastfeeding status in women of childbearing age prior to each injection, as part of anti-VEGF treatment protocols.
MgHPO4.3H2O is prepared by simultaneously introducing into a reactor phosphoric acid and/or solutions of monoalkali metal phosphates and solutions of a magnesium salt and an alkali metal hydroxide and/or carbonate, if desired in the presence of additional water, reacting the solutions by rapidly and intimately mixing them, and filtering and recovering the product. The solutions may contain less than 0.1 wt. per cent of impurities, e.g. Fe, Co, Ni, V, Cr and Mn. The reaction may be carried out at a pH between 2.5 and 6.5 at a temperature between 20 DEG  and 80 DEG  C.  The Mg salt and the alkali metal hydroxide and/or carbonate may be introduced in a stoichiometric quantity so as to maintain a pH of 2.5 to 6.5.  The grain size of the product may be below or above 40 m  depending on the particular reaction conditions used.  The initial solution may be a 25-35 wt. per cent solution of MgCl2 or Mg(NO3)2 and a 50-80 wt. per cent solution of H3PO4 or its monoalkali salts, and a 30-50 wt. per cent solution of the alkali metal hydroxide or carbonate.
Childhood cancer survivors who have been treated for a sarcoma who did not receive pelvic radiation, and were treated with chemotherapy, with or without surgical intervention or radiation therapy (outside of the pelvis). These patients will be matched as closely as possible to Group 1 to match chemotherapy regimens, and sex.
The dosimetric scanner needed to calculate the dose to be delivered to the tissues will be carried out according to the standard practice. The treatment plan will be carried out by the physicist in accordance with the dose constraints and validated by the radiation therapist. Each treatment session is preceded by positioning imaging to ensure high precision in the treated area. During the first session, the acquisition of the positioning scanner will take into account the entire region of the target volume in accordance with the classic treatment protocol. Usually, the positioning scans of the remaining sessions are carried out on a smaller area around the operating bed in order to reduce the acquisition time. However, in the context of this study, mid- and end-of-treatment positioning scans will be acquired over the same exploration range as on the first day. These scanners will make it possible to compare the contouring work carried out manually by the radiotherapist and that obtained by the deformable registration algorithm.
Patients with type 1 (T1D) or type 2 diabetes (T2D) hospitalized (\>24h) and presenting at least a risk factor for readmission after discharge at home, will be randomized, at time of discharge, between 2 groups: an "intervention" group and a control group (usual management). Intervention will consist in optimized organization of discharge at home followed by a ambulatory individualized coaching by a nurse including an initial situation assessment, a consultation meeting with the patient's GP in order to propose a Health Personalized Plan, then a follow up program with a face to face session each trimester in order to remind the objectives, to assess compliance to the plan, to evaluate difficulties encountered and to help to find solutions. Final data collection will be done in both groups by questioning the patient's general practitioner (GP) and by collecting data on potential hospitalization. Expected duration : 3 years. Readmission rate, duration and causes of hospitalization will be compared between both groups. Impact of the results : Reduction of costs, improved use of hospital specialized resources.
1313207 Preparing 7-amino-cephalosporanic acid; N-haloalkanoylcephalosporins ELI LILLY & CO 24 June 1970 [26 June 1969] 30753/70 Heading C2A [Also in Division C3] 7-Amino-cephalosporanic acid is prepared from cephalosporin C by acylating the amino group in the adipamyl side chain with an α- halo- or α,α-dihalo-C 2 to C 4 alkanoyl group, protecting the carboxyl groups, treating with a halogenating agent to convert the amido group in the 7-position to an imino halide, converting the imino halide to an imino ether, hydrolysing the imino ether and if necessary, removing the carboxyl-protecting groups, to give 7-aminocephalosporanic acid. The amino group is preferably acylated with a chloroacetyl group, suitably while the cephalosporin C is still in the preparative fermentation broth. The N-haloalkanoyl derivative is extracted with waterimmiscible solvent (e.g. alkyl esters preferably with 1/10 volume of alkanol) and precipitated from the extract as a salt. The preferred salt is an amine salt, since the subsequent reaction for protecting the carboxyl groups proceeds more rapidly with better yields if an amine salt is used. The carboxyl groups arc protected by esterification, preferably as a silyl ester by treatment with an alkylchlorosilane. The imino halide is formed by reaction with a halogenating agent such as a chloride or oxychloride of phosphorus, sulphur or carbon, preferably phosphorus pentachloride, and is converted to the imino ether by reaction with an alcohol, a phenol or a sulphydryl compound, e.g. npropanol. The imino ether is hydrolysed or alcoholysed by treatment with water or an alcohol under mildly acidic or basic conditions; this treatment may also remove the carboxylprotecting ester groups, or alternatively they may be removed by other conventional procedures, e.g. hydrogenolysis. Novel N - α - haloalkanoyl cephalosporins having the formula wherein R is an α-halo- or α,α-dihalo-C 2 to C 4 alkanoyl group and X is hydrogen or C 1 -C 4 alkyl, C 4 -C 8 t-alkyl, C 5 -C 8 t-alkenyl, C 5 -C 8 talkynyl, phenacyl, trichloromethyl, benzyl, benzhydryl, p-methoxybenzyl, p-nitrobenzyl, trityl, trimethylsilyl, dimethylsilyl, methylsilyl, triethylsilyl, diethylsilyl, or ethylsilyl, and the alkali metal, alkaline earth metal, quinoline, cyclohexylamine, 5-ethyl-2-methylpyridine, 2-, 3- or 4-picoline, N-ethyl or N-methylmorpholine, 2,6-lutidine, N,N-diethylcyclohexylamine, hexamethylenetetramine, N,N - dimethylbenzylamine or N,N-dibenzylethylenediamine salt thereof when one or both X groups are hydrogen, are prepared by treating cephalosporin C with an appropriate haloacyl halide or mixed anhydride and if required, salifying the product. Reference has been directed by the Comptroller to Specification 1,041,985.
[GB1313207A]
We aimed to verify the characteristics of lifestyles and frailty among older adults during and after the COVID-19 pandemic. This two-point cross-sectional study conducted a baseline survey (BL) in 2020 and a follow-up survey (FU) in 2023 with community-dwelling individuals aged ≥65 years in Japan. The 700 and 572 participants in the BL and FU were analyzed. We compared frailty occurrence and lifestyle characteristics between both surveys. In the BL and FU, 38.3 %, 52.4 %, and 9.3 % and 29.4 %, 59.4 %, and 11.2 % of the individuals were classified as robust, pre-frail, and frail, respectively, showing a significant decrease in the number of robust, and an increase in the number of pre-frail. A significant decrease in dietary intake was observed among robust individuals in the FU, with an overall significant decrease in communication opportunities in the BL. Therefore, lifestyle changes due to infection control measures may have a delayed impact on frailty.